OFFICIAL PUBLICATION OF

by its subsidiary APPco

High Court decision could undermine development of innovative medicines

Megan Haggan 07/10/2015

The High Court decision to disallow patenting of isolated genetic materials is a worry for the innovative medicines sector, says Medicines Australia. “It is essential that Australia maintains strong and stable intellectual property protection that will support the development of new biological medicines,” says Medicines Australia CEO Tim James. “We will need to consider the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

Wesfarmers targets affordable healthcare

When healthcare is treated as a commodity and patients regarded as consumers, health outcomes are compromised and overall healthcare spending…

Edward Hatfield

High Court decision could undermine development of innovative medicines

Previous Lifestyle change could reduce cancer by 37,000 cases a year

Next New insights into 90-year-olds show we need better knowledge

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Lifestyle change could reduce cancer by 37,000 cases a year

Next New insights into 90-year-olds show we need better knowledge

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.